SCHEMBL3348291

SCHEMBL3348291

Cc1nc2ccccn2c1-c1nc(C2(c3ccc(C(=O)NO)cc3)CC2)sc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.38
AKT2 P31751 2/20 0.38
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
CDK2 P24941 2/20 0.37
CDK4 P11802 1/20 0.37
CCNE1 P24864 1/20 0.37
HSD17B10 Q99714 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.36
HDAC1 Q13547 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PIM1 P11309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350719 0.96 AKT1 (0.39) AKT1AKT2KDM4EALDH1A1GAA
SCHEMBL197516 0.94 GAA (0.39) AKT1AKT2KDM4EALDH1A1GAA
SCHEMBL3352141 0.91 AKT1 (0.39) AKT1AKT2KDM4EALDH1A1GAA
SCHEMBL3353718 0.87 HDAC1 (0.52) CDK2CDK4CCNE1HDAC1
SCHEMBL3354200 0.84 PIK3CA (0.40) KDM4EALDH1A1POLBMAPTHPGD
SCHEMBL197109 0.84 CDK2 (0.47) KDM4EALDH1A1GAAKMT2ACDK2
SCHEMBL3352620 0.84 HDAC1 (0.51) CDK2CDK4CCNE1HDAC1
SCHEMBL199437 0.82 HDAC1 (0.49) GAAPOLBMAPTHDAC1
SCHEMBL3356956 0.81 MARK3 (0.41) AKT1AKT2KDM4EALDH1A1MAPT
SCHEMBL3356335 0.81 CDK2 (0.46) AKT1AKT2KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 AKT1 1338/4885AKT2 981/4885KDM4E 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.